CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) Structural Biophysics Guided Computational Design of Semaglutide Analogues to Enhance GLP 1R Activation Article (Preprint v1) by Wei Li Qeios In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide Lumin Peptides Cagrilintide 10mg Peptides Alpha